Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
GRIN Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06975605CT.gov Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs. | — | Completed | — | — | — |
NCT06965881CT.gov Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults | — | Terminated | — | — | — |
NCT06392009CT.gov Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Tuberous Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Radiprodil (this asset) | GRIN Therapeutics, Inc. | P1/2 | CCC · 48 |
| Everolimus | Hospices Civils de Lyon | P3 | BBB |
| Sirolimus | Katarzyna Kotulska | P3 | BBB |
| Npc-12G | Nobelpharma | P3 | BB |
| Ganaxolone | Marinus Pharmaceuticals | P3 | BB |
| Neurotop | GRIN Therapeutics, Inc. | P3 | BB |
| Npc-12Y Gel | Nobelpharma | P3 | BB |
| Vigabatrin | Katarzyna Kotulska | P2/3 | BB |
| Doxycycline | University of Nottingham | P4 | BB |
+13 more in the Tuberous Sclerosis cohort
Other indications for Radiprodil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Isolated Focal Cortical Dysplasia | — | P1/2 | CCC · 50 |
| Diabetic Neuropathy | — | P2 | CCC · 49 |
| Infantile Spasms | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Radiprodil in Tuberous Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/radiprodil-tuberous-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →